Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 9, 26 | -1.25 Decreased by -60.26% | -1.58 Increased by +20.69% |
| Nov 12, 25 | -1.90 Decreased by -65.22% | -1.28 Decreased by -48.44% |
| Aug 5, 25 | -1.44 Decreased by -60.00% | -1.23 Decreased by -17.07% |
| May 5, 25 | -1.39 Decreased by -67.64% | -1.07 Decreased by -29.69% |
| Mar 10, 25 | -0.78 Increased by +56.91% | -1.26 Increased by +38.04% |
| Nov 5, 24 | -1.15 Increased by +43.90% | -0.95 Decreased by -21.05% |
| Aug 6, 24 | -0.90 Increased by +56.10% | -1.19 Increased by +24.37% |
| May 7, 24 | -0.83 Increased by +80.42% | -1.09 Increased by +23.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | N/A Decreased by -100.00% | -20.55 M Decreased by -115.69% | - - |
| Sep 30, 25 | 0.00 Decreased by N/A% | -23.34 M Decreased by -69.35% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -17.66 M Decreased by -76.67% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -16.98 M Decreased by -146.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 703.38 K Decreased by -47.89% | -9.53 M Decreased by -18.81% | Decreased by -1.35 K% Decreased by -127.99% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -13.78 M Decreased by -37.10% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -10.00 M Decreased by -13.81% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -6.90 M Increased by +61.12% | Decreased by N/A% Decreased by N/A% |